Synereca Pharmaceuticals was created to address the growing problem of bacterial resistance to current antibiotics by developing drugs that restore or increase the effectiveness of existing antibiotics.
Synereca’s discovery program has identified 5 chemical subclasses of compounds that potentiate the effectiveness of current classes of antibiotics, including polymyxins, carbapenems, aminoglycosides, and fluoroquinolones.
The Company’s lead program focuses on compounds that potentiate the effectiveness of Colistin, the last line of defense against resistant Gram-Negative bacterial infections, without enhancing toxicity. The Colistin potentiation program’s lead compounds shift the Minimum Inhibitory Concentration (MIC100) of Colistin in several species Gram-Negative bacteria from 16-fold to over 4,000-fold in vitro in susceptible and resistant isolates of K. pneumoniae, E. coli, A. baumannii, and P. aeruginosa. Candidates have also demonstrated ability to reduce the protective dose (PD50) of Colistin in an in vivo preclinical model of infection caused by a multi-drug resistant strain of Acenitobacter baumanni.
Additional preclinical efforts on the potentiation of other antibiotic classes is underway.